

# The Role of Ultrasound in Obstetric Hemorrhage

Janet M Burlingame

Assistant Professor, Division of Maternal Fetal Medicine, Department of Obstetrics, Gynecology and Women's Health John A Burns School of Medicine, University of Hawaii, Honolulu, Hawaii, USA

**Correspondence:** Janet M Burlingame, Department of Obstetrics, Gynecology and Women's Health, University of Hawaii John A Burns School of Medicine, 1319 Punahou Street, Suite 824, Honolulu, Hawaii 96826, USA, Phone: (808)203-6500 Fax: (808)955-2174, e-mail: burlinga@hawaii.edu

## Abstract

Ultrasound assists in the diagnosis and management of obstetric hemorrhage. With improving technology and increasing availability, there has been a decreased morbidity and mortality from obstetric hemorrhage due to ectopic pregnancy, vasa previa and abnormal placentation. There is also theoretic benefit for the use of ultrasound in less common conditions such as uterine varix. The goal of this article is to review the common causes of obstetric hemorrhage; to review the ultrasound findings in these causes; and to discuss the intraoperative use of ultrasound in the treatment of obstetric hemorrhage.

### Objectives

- Review common causes of obstetric hemorrhage
- Review the ultrasound findings of these causes
- Discuss the role of ultrasound during procedures for obstetric hemorrhage

**Keywords:** Obstetric hemorrhage, ultrasound, placenta.

## INTRODUCTION

Obstetric hemorrhage is one of the leading causes of maternal mortality (within 42 days of birth) worldwide accounting for 25 to 30% of maternal deaths. Maternal mortality due to hemorrhage in the early antepartum period is attributed mainly to ectopic pregnancies, molar pregnancies and abortions. The rate of death per 100,000 live births from 1974 to 1978 was 2.1 and from 1979 to 1992 decreased to 1.3. It is reasonable to assume that improved diagnosis using such modalities as ultrasound has decreased maternal mortality.<sup>1,2</sup>

Obstetric hemorrhage is a common and often daunting clinical emergency. In the late antepartum obstetric hemorrhage complicates 2 to 5% of all pregnancies with, and abruption accounts for approximately, 18.5% of all cases of obstetric hemorrhage.<sup>3</sup>

Fetal outcome is also affected by obstetric hemorrhage. For example, in maternal hemorrhage resulting in maternal death, a live birth occurs only 56% of the time.

A stillbirth occurs 16% of the time, and 6.3% of women die undelivered.<sup>4</sup>

For aid in ultrasound and clinical diagnosis it is useful to break the causes of obstetric hemorrhage into groups by time in gestation when they occur, such as early and late antepartum and postpartum periods (Table 1).

**Table 1:** Common causes of obstetric hemorrhage by stage of pregnancy (causes discussed in this article are highlighted)

	Early	Late
Antepartum	<ul style="list-style-type: none"> <li>• Ectopic pregnancy</li> <li>• Molar pregnancy</li> <li>• Abortion (medical or spontaneous)</li> </ul>	<ul style="list-style-type: none"> <li>• Placental abruption</li> <li>• Placenta previa</li> </ul>
Postpartum	<ul style="list-style-type: none"> <li>• Uterine atony</li> <li>• Myomas</li> <li>• Retained products</li> <li>• Invasive placentation</li> <li>• Uterine rupture</li> <li>• Uterine inversion</li> <li>• Coagulopathy</li> <li>• Lacerations of genital tract – Lower and upper</li> </ul>	<ul style="list-style-type: none"> <li>• Infection</li> <li>• Retained products</li> <li>• Subinvolution of placental site</li> <li>• Coagulopathy</li> <li>• Uterine varix</li> </ul>

This article will review some of the common causes of obstetric hemorrhage, other than ectopic pregnancy, with emphasis on those causes that can be diagnosed and/or managed with help of ultrasound imaging.

## UTERINE ATONY

Uterine atony or the inability for the myometrium to contract after delivery of the placenta is perhaps the most common cause of obstetric hemorrhage.<sup>2</sup> Because 300 to 600 cc/min of blood circulates through a term gravid uterus which is 2 to 17% of the maternal cardiac output, uterine atony is

a clinical emergency and if not treated immediately can lead to death.<sup>5,6</sup> In certain instances, ultrasound can help to predict women at risk for uterine atony such as myomas, retained placental tissue and abnormal placentation.

## MYOMAS

Myomas can be recognized with ultrasound in 10.7% off all pregnancy with rates as high as 18% in African American women.<sup>7</sup> There is an increased risk of postpartum hemorrhage regardless of size. Qidwai et al demonstrated that from 1993 to 2003, 15,104 women underwent routine second trimester prenatal ultrasonography, and only 401 (2.7%) women were identified with at least 1 leiomyoma. However, this group of women had an odds ration of 2.57 (95% CI 1.54 to 4.27) risk of obstetric hemorrhage.<sup>8-11</sup>

More rare complications of myomas in pregnancy include spontaneous hemoperitoneums and hypovolemic shock to massive edema of a pedunculated myoma.<sup>12,13</sup>

## RETAINED PRODUCTS

It is important to remember that the clinical history is extremely important when interpreting the ultrasound images of retained products (usually placental), as the sensitivity and positive predictive value of ultrasound can be marginal. Retained products should be considered in instances of persistent bleeding after a spontaneous or induced abortion or a preterm or term delivery. In up to 15% of postpartum uteri, retained products have been observed with ultrasound. When correlated with uterine exploration and curettage, the sensitivity, specificity, positive and negative predictive value of ultrasound in predicting retained products were 44, 92, 58 and 87%, respectively.<sup>14</sup> Echogenic mass seems to be the most common finding immediate postpartum finding in documented retained products (Figure 1), however recent instrumentation can lead to a false positive result, and therefore ultrasound is more reliable prior to instrumentation. The finding with the best negative predictive value was a normal uterine stripe.<sup>14,15</sup>

Succenturiate lobes occur in 10% of placentas, and they are a risk factor for retained placental tissue and obstetric hemorrhage.<sup>16-18</sup> If a succenturiate lobe is not anticipated, what appears to be an intact placenta will lead to the false clinical assumption that the uterus is empty postpartum. On ultrasound, a succenturiate lobe appears a separate placental mass connected to the main placenta by intramembranous vessels (Figure 2). It sometimes look like



Figure 1: Retained placental tissue after term delivery



Figure 2: Succenturiate placental lobe

a placental abruption and can be confused with a myometrial contraction or even a placental infarction.<sup>19</sup> Succenturiate lobes have also been associated with artificial reproductive technologies.<sup>18</sup> When a succenturiate lobe is identified it should prompt evaluation for possible vasa previa.<sup>16,18,20-28</sup>

## VASA PREVIA

Vasa previa is defined as fetal vessels traversing the fetal membranes free of placental tissue in the lower uterine segment near the internal cervical os. Vasa previa occurs in approximately 1:3000 births. There is a high fetal mortality (22 to 100%) associated with vasa previa resulting in vessel rupture and fetal exsanguination.<sup>29-31</sup> The advent of transvaginal imaging and doppler technologies have improved the diagnosis of vasa previa and thereby decreased but not eliminated the high morbidity and mortality. Doppler

waveform can be crucial in identifying fetal vessel waveforms. One of the pitfalls of diagnosing a vasa previa is differentiating between a free-floating loop of umbilical cord. It is important to document that the suspect fetal vessels do not move with fetal position change and that they persist on subsequent exams and are not surrounded by amniotic fluid. Succenturiate lobes, low-lying placentas, bilobate placentas and velamentous cord insertion are risk factors. These risks should prompt mapping of the placental cord insertion and the use of transvaginal doppler mapping if a vasa previa is suspected.<sup>20-26,29,30,32</sup>

### PLACENTA PREVIA AND LOW-LYING PLACENTA

Placenta previa occurs in approximately 0.5% all pregnancies but is seen in 4% ultrasound done in the second trimester.<sup>33, 34</sup> Approximately, 85% of previas diagnosed in the second trimester “resolve” by the time of delivery probably due to the expansion of the lower uterine segment increasing the distance from the placental edge to the internal os. Placental infarction has also been attributed to the resolution of placenta previas. Risk factors for placenta previa include age, parity, previous cesarean, smoking, and prior abortion. Ultrasound was first used to diagnose placenta previa in 1966.<sup>35</sup> Transabdominal imaging has a 2 to 7% false-positive and 2 to 8% false-negative and transvaginal imaging has a false positive and false-negative rate of approximately 1 to 2%.<sup>36-41</sup> Transperineal and transrectal ultrasonography have also been used successfully in diagnosing placental previa.<sup>36, 42, 43</sup> When imaging the placental edge it is important to have the endocervical stripe visualized and if possible some amniotic fluid for contrast between the internal cervical os and the presenting fetal part. An overdistended maternal bladder or a contraction in the lower uterine segment can leave to false positive findings.


Placenta previas have been categorized into both clinical and ultrasonographic classifications. The terms of marginal versus partial were a traditionally clinical diagnosis used at the time of a “double set up” manual exam after cervical dilation while in labor. This terminology has changed with the refinement of ultrasound. If the leading edge of the placenta in relation to the internal os  $>2$  cm this is not a previa. If the placenta covers the os it is termed a complete previa. A “low-lying” should be described in terms of centimeters from the internal os because of the varied clinical outcomes. For example, most recent studies suggest that if the distance to the os is  $< 1$  cm treat, then the pregnancy should be treated as a previa with a planned cesarean

delivery. At 1 to 2 cm from the internal os there is a more debatable risk of cesarean secondary to hemorrhage which is anywhere from 23.5 to 90%.<sup>33,44,45</sup> Other studies have shown no correlation between clinical outcome and placental edge to internal cervical os distance.<sup>46</sup>

### PLACENTA ACCRETA

Placenta accreta, increta and percreta represent a spectrum of invasive placentations that do not respect the myometrial border. These types of invasive placentations are associated with a maternal mortality quoted as high as 7 to 15% and a transfusion rate as high as 90%. Depth of invasion has an important influence on maternal morbidity and clinical management. Accreta occurs in 78% of cases and is defined as placental invasion through the Stratum Basalis of the endometrium and approximating the myometrium. Increta occurs in 17% of cases and is defined as placental invasion into the myometrium. Percreta occurs in 5% of cases and is defined as placental invasion through the myometrium and into or past the serosa.

Prenatal diagnosis of invasive implantation can reduce maternal morbidity and mortality.<sup>47-51</sup> Ultrasound is typically 89 to 93% sensitive in detecting placenta accreta in high-risk women.<sup>52,53</sup> Common ultrasound findings are a disrupted placenta-myometrial interface, myometrial thickness  $< 1$  mm, cystic lacunae and hypervascularity of bladder and uterine serosa (Figure 3), prominent subplacental venous complex; loss of subplacental doppler signals, and a tissue mass outside the uterus.<sup>47,53,54</sup> Ultrasound is still considered the first line imaging modality to detect placenta accreta. However, MRI is increasing in popularity as expertise with MRI in obstetrics is increasing. At this time



**Figure 3:** Doppler used to visualize hypervascularity with bladder wall invasion by a placenta percreta

there is no clear cut evidence that supports the use of MRI over ultrasound in the diagnosis of placenta accreta.<sup>51,52,54,55</sup> Personal experience suggests that MRI may have some benefit in diagnosing and describing suspected posterior accretas or lateral percretas.

Use of MRI has been helpful in some hands. MRI's accuracy rate varies from 38 to 97%. This may be due to the varied experience of the radiologist interpreting the images. Typically, MRI's best detection rate is for posterior incretas and percretas.

## PLACENTAL ABRUPTION

Clinically evident placental abruption occurs in approximately 0.6 to 1.7% of all pregnancies and occurs most commonly at the placental edge.<sup>56-60</sup> Although, ultrasound is a useful tool in detecting placental abruptions and predicting clinical outcome, ultrasound should not to be relied on in basing clinical decisions. Hemorrhage due to placental abruption may cause significant clinical impact without any retroplacental clot visualized by transabdominal or transplacental ultrasound. Detection of a retroplacental clot is variable and has been estimated at any where from 11 to 80%.<sup>60-67</sup> The positive predictive value of ultrasound to diagnose abruption is much higher than the relatively poor predictive value of ultrasound, 88% and 53% respectively.<sup>63</sup> The ability to detect placental abruption with ultrasound depends on the location, size and the age of the abruption. Nyberg and associates described the ultrasonographic appearance of acute and chronic abruptions in a retrospective cohort of 57 cases. Although, abruption may just appears as a heterogeneous and thickened placenta, they found that




Figure 4: Hyperechoic blood collection near the internal os



Figure 5: Retroplacental hypoechoic clot

in the acute phase the abruption was typically hyperechoic (0 to 48 hours duration) (Figure 4) or isoechoic (3 to 7 days duration) in relation to the placenta. After one week duration the abruption was hypoechoic (Figure 5) and after 2 weeks the abruption was typically sonolucent.<sup>64</sup> The volume (> 60 ml) and location (retroplacental) of the abruption and percent (30 to 40%) of the placental surface involved in the abruption has also been found to negatively correlate with fetal mortality and morbidity such as intrauterine growth restriction.<sup>68</sup>

## UTERINE RUPTURE

The diagnosis of uterine rupture is primarily clinical.<sup>69</sup> It is often based on historical risk factors, abdominal pain, and a change in fetal station, uterine bleeding, and fetal intolerance of labor. However, ultrasound can be useful as a supportive tool. It can be used to visualize a hemoperitoneum, check for fetal location, visualization of a prior uterine scar with absence of myometrium and possibly a bulging amniotic sac.<sup>70-75</sup> Ultrasound has also been used to predict women at risk for uterine rupture or dehiscence after prior cesarean birth with varying degrees of success.<sup>76-78</sup> On average the average full lower uterine segment (LUS) thickness (defined as the shortest distance between the urinary bladder wall-myometrium interface and the myometrium/chorioamniotic membrane-amniotic fluid interface) in women with a prior cesarean delivery is 1.8 to 2.8 mm.<sup>76,78</sup> Cheung and associates demonstrated that a sonographic LUS thickness of 1.5 mm had a sensitivity of 88.9%, a specificity of 59.5%, a positive predictive value of 32.0%, and a negative

predictive value of 96.2% in predicting a paper-thin or dehiscent LUS.<sup>78</sup> Bujold and associates demonstrated that only full LUS thickness (OR, 4.66; 95% confidence interval, 1.04-20.91) vs just the myometrial thickness were predictive of uterine rupture. In this study a short interdelivery interval (<18 months) and a single layer closure were also associated with uterine rupture and dehiscence.<sup>76</sup> Transvaginal measurements of the lower uterine segment thickness have been found to be superior.<sup>79</sup>

## MOLAR PREGNANCY

Molar pregnancy is a potential cause of obstetric hemorrhage in the first and/or early second trimester. It occurs approximately 1:1000 pregnancies. Rarely a molar pregnancy can coexist with a live pregnancy, and this occurs in 1:20,000-100,000 pregnancies (Figure 6). Clinical symptoms associated with molar pregnancies include hyperemesis, thyrotoxicosis and hypertension.<sup>80-85</sup> Clinical signs include bleeding, uterine enlargement and theca-lutein cysts. Vesicles may be observed being passed from the vagina.

There are two different types of molar pregnancies, complete and partial, with different ultrasound findings and varied clinical courses.<sup>86, 87</sup> Complete moles are diploid (paternal origin). 90% of partial moles are triploid. Diandric partial moles (two sets of paternal chromosomes) usually have a thicker placenta and the digynic partial moles (two sets of maternal chromosomes) appear to have a more normal placenta and often do not develop vesicles until later in the first trimester.

The classic finding is hydropic vesicles often described as a “snow storm” appearance and more common in the complete molar pregnancies. Other supportive findings on ultrasound include an echogenic placental mass, theca-lutein



**Figure 6:** An incomplete mole with embryonic tissue

cysts and the absence of a gestational sac with an increasing placental mass and rising hCG levels. When a fetus exists in partial molar pregnancies they are often incomplete or severely growth retarded.<sup>88-94</sup> Because molar pregnancies change appearance with time as the hydropic vesicles become more obvious, ultrasound becomes less sensitive the earlier it is performed in pregnancy.<sup>95</sup> Overall sensitivity of transvaginal ultrasound in diagnosing molar pregnancy is 50 to 86% with the increased sensitivity for complete molar pregnancy of approximately 80% vs for partial molar pregnancy of approximately 30%.<sup>94, 96, 97</sup> Doppler has also been used with some limited success in determining which postpartum women will progress to have gestational trophoblastic neoplastic disease.<sup>98, 99</sup>

## UTERINE VARIX

A rare but clinically challenging cause of delayed postpartum hemorrhage is the uterine varix or arterio-venous malformation (AVM). Typically these lesions occur after a cesarean or postpartum curettage, and they present as recurrent heavy vaginal bleeding that does not respond to medical therapy.<sup>100-105</sup> Ultrasound with color and duplex doppler technology can be essential in the diagnosis of this rare disorder. Pseudoaneurysms, often demonstrate a blood-filled cystic structure with swirling arterial flow. AVMs often demonstrate intense vascular tangle on color Doppler and low-resistance and high-velocity arterial flow on duplex doppler. AVMs combined with a pseudoaneurysm demonstrate the findings of both AVMs and pseudoaneurysms.<sup>104</sup>

## CONCLUSION

Ultrasound has been used since 1966 to help diagnose causes of obstetric hemorrhage.<sup>35</sup> Although ectopic pregnancy is one of the most common clinical problems resulting in obstetric hemorrhage, there are many other diagnoses that contribute to the overall maternal morbidity and mortality due to obstetric hemorrhage. In this article we have reviewed some common and rare causes of obstetric hemorrhage that can be diagnosed and managed with ultrasound. In some instances such as previa sensitivity can be as high as 98% and in others as low as 30% (partial molar pregnancy), but in all instances ultrasound has the potential to reduce morbidity and improve outcome. When the problem of obstetric hemorrhage presents to the clinician in any trimester or in the postpartum period, a thorough transvaginal and

transabdominal ultrasound exam with Doppler technology should be undertaken with the knowledge of ultrasound's strengths and limitations. Often recurrent ultrasound exams may be required to secure a diagnosis as in vasa previa, molar pregnancy, myomas and uterine wall thickness.

## REFERENCES

1. Devine PC. Obstetric hemorrhage. *Semin Perinatol* 2009;33:76-81.
2. Mercier FJ, Van de Velde M. Major obstetric hemorrhage. *Anesthesiol Clin* 2008;26:53-66.
3. Kaunitz AM, Hughes JM, Grimes DA, Smith JC, Rochat RW, Kafriksen ME. Causes of maternal mortality in the United States. *Obstet Gynecol* 1985;65:605-12.
4. Chichakli LO, Atrash HK, MacKay AP, Musani AS, Berg CJ. Pregnancy-related mortality in the United States due to hemorrhage: 1979-1992. *Obstet Gynecol* 1999;94:721-25.
5. Thaler I, Manor D, Itskovitz J, et al. Changes in uterine blood flow during human pregnancy. *Am J Obstet Gynecol* 1990;162:121-25.
6. Ferris TF, Stein JH, Kauffman J. Uterine blood flow and uterine renin secretion. *J Clin Invest* 1972;51:2827-33.
7. Laughlin SK, Baird DD, Savitz DA, Herring AH, Hartmann KE. Prevalence of uterine leiomyomas in the first trimester of pregnancy: An ultrasound-screening study. *Obstet Gynecol* 2009;113:630-35.
8. Gupta S, Manyonda IT. Acute complications of fibroids. *Best Pract Res Clin Obstet Gynaecol* 2009;23:609-17.
9. Qidwai GI, Caughey AB, Jacoby AF. Obstetric outcomes in women with sonographically identified uterine leiomyomata. *Obstet Gynecol* 2006;107:376-82.
10. Ouyang DW, Economy KE, Norwitz ER. Obstetric complications of fibroids. *Obstet Gynecol Clin North Am* 2006;33:153-69.
11. Koike T, Minakami H, Kosuge S, et al. Uterine leiomyoma in pregnancy: Its influence on obstetric performance. *J Obstet Gynaecol Res* 1999;25:309-13.
12. Koide K, Sekizawa A, Nakamura M, Matsuoka R, Okai T. Hypovolemic shock due to massive edema of a pedunculated uterine myoma after delivery. *J Obstet Gynaecol Res* 2009;35:794-96.
13. Wong L, Ching TW, Kok TL, Koon TH. Spontaneous hemoperitoneum from a uterine leiomyoma in pregnancy. *Acta Obstet Gynecol Scand* 2005;84:1208-09.
14. Carlan SJ, Scott WT, Pollack R, Harris K. Appearance of the uterus by ultrasound immediately after placental delivery with pathologic correlation. *J Clin Ultrasound* 1997;25:301-08.
15. Hertzberg BS, Bowie JD. Ultrasound of the postpartum uterus. Prediction of retained placental tissue. *J Ultrasound Med* 1991;10:451-56.
16. Hata K, Hata T, Aoki S, Takamori H, Takamiya O, Kitao M. Succenturiate placenta diagnosed by ultrasound. *Gynecol Obstet Invest* 1988;25:273-76.
17. Nelson LH, Fishburne JI, Stearns BR. Ultrasonographic description of succenturiate placenta. *Obstet Gynecol* 1977;49:79-80.
18. Suzuki S, Igarashi M. Clinical significance of pregnancies with succenturiate lobes of placenta. *Arch Gynecol Obstet* 2008;277:299-301.
19. Leekam RN. Placental infarction simulating a succenturiate lobe. *J Clin Ultrasound* 1995;23:251-53.
20. Baulies S, Maiz N, Munoz A, Torrents M, Echevarria M, Serra B. Prenatal ultrasound diagnosis of vasa praevia and analysis of risk factors. *Prenat Diagn* 2007;27:595-99.
21. Lijoi AF, Brady J. Vasa previa diagnosis and management. *J Am Board Fam Pract* 2003;16:543-48.
22. Chihara H, Otsubo Y, Ohta Y, Araki T. Prenatal diagnosis of succenturiate lobe by ultrasonography and color Doppler imaging. *Arch Gynecol Obstet* 2000;263:137-38.
23. Lee W, Lee VL, Kirk JS, Sloan CT, Smith RS, Comstock CH. Vasa previa: Prenatal diagnosis, natural evolution, and clinical outcome. *Obstet Gynecol* 2000;95:572-76.
24. Meizner I, Mashiach R, Shalev Y, Ben-Rafael Z. Blood flow velocimetry in the diagnosis of succenturiate placenta. *J Clin Ultrasound* 1998;26:55.
25. Meyer WJ, Blumenthal L, Cadkin A, Gauthier DW, Rotmensch S. Vasa previa: Prenatal diagnosis with transvaginal color Doppler flow imaging. *Am J Obstet Gynecol* 1993;169:1627-29.
26. Nelson LH, Melone PJ, King M. Diagnosis of vasa previa with transvaginal and color flow Doppler ultrasound. *Obstet Gynecol* 1990;76:506-09.
27. Spirt BA, Kagan EH, Gordon LP, Massad LS. Antepartum diagnosis of a succenturiate lobe: Sonographic and pathologic correlation. *J Clin Ultrasound* 1981;9:139-40.
28. Radman HM. Succenturiate lobe of the placenta with vasa previa and prolapse of the umbilical cord. *Sinai Hosp J (Balt)* 1958;7:11-13.
29. Oyelese KO, Turner M, Lees C, Campbell S. Vasa previa: An avoidable obstetric tragedy. *Obstet Gynecol Surv* 1999;54:138-45.
30. Oyelese KO, Schwarzler P, Coates S, Sanusi FA, Hamid R, Campbell S. A strategy for reducing the mortality rate from vasa previa using transvaginal sonography with color Doppler. *Ultrasound Obstet Gynecol* 1998;12:434-38.
31. Fung TY, Lau TK. Poor perinatal outcome associated with vasa previa: Is it preventable? A report of three cases and review of the literature. *Ultrasound Obstet Gynecol* 1998;12:430-33.
32. Gagnon R, Morin L, Bly S, et al. Guidelines for the management of vasa previa. *J Obstet Gynaecol Can* 2009;31:748-60.
33. Oppenheimer L. Diagnosis and management of placenta previa. *J Obstet Gynaecol Can* 2007;29:261-73.
34. Mustafa SA, Brizot ML, Carvalho MH, Watanabe L, Kahhale S, Zugaib M. Transvaginal ultrasonography in predicting placenta previa at delivery: A longitudinal study. *Ultrasound Obstet Gynecol* 2002;20:356-59.
35. Gottesfeld KR, Thompson HE, Holmes JH, Taylor ES. Ultrasonic placentography: A new method for placental localization. *Am J Obstet Gynecol* 1966;96:538-47.
36. Heer IM, Muller-Egloff S, Strauss A. Placenta praevia: Comparison of four sonographic modalities. *Ultraschall Med* 2006;27:355-59.
37. Tan NH, Abu M, Woo JL, Tahir HM. The role of transvaginal sonography in the diagnosis of placenta praevia. *Aust NZJ Obstet Gynaecol* 1995;35:42-45.
38. Kaur H, Sarin AR, Kaur RP. Role of sonography in placenta previa. *Indian J Matern Child Health* 1993;4:111-13.
39. Timor-Tritsch IE, Monteagudo A. Diagnosis of placenta previa by transvaginal sonography. *Ann Med* 1993;25:279-83.

40. Leerentveld RA, Gilberts EC, Arnold MJ, Wladimiroff JW. Accuracy and safety of transvaginal sonographic placental localization. *Obstet Gynecol* 1990;76:759-62.
41. Farine D, Peisner DB, Timor-Tritsch IE. Placenta previa: Is the traditional diagnostic approach satisfactory? *J Clin Ultrasound* 1990;18:328-30.
42. Rani PR, Haritha PH, Gowri R. Comparative study of transperineal and transabdominal sonography in the diagnosis of placenta previa. *J Obstet Gynaecol Res* 2007;33:134-37.
43. Adeyomoye AA, Ola ER, Arogundade RA, Awosanya GO, Abudu OO. Comparison of the accuracy of transabdominal sonography (TAS) and transperineal sonography (TPS) in the diagnosis of Placenta Praevia. *Niger Postgrad Med J* 2006;13: 21-25.
44. Bronsteen R, Valice R, Lee W, Blackwell S, Balasubramaniam M, Comstock C. Effect of a low-lying placenta on delivery outcome. *Ultrasound Obstet Gynecol* 2009;33:204-08.
45. Bhide A, Prefumo F, Moore J, Hollis B, Thilaganathan B. Placental edge to internal os distance in the late third trimester and mode of delivery in placenta praevia. *BJOG* 2003;110: 860-64.
46. Matsubara S, Ohkuchi A, Kikkawa M, et al. Blood loss in low-lying placenta: Placental edge to cervical internal os distance of less vs. more than 2 cm. *J Perinat Med* 2008;36:507-12.
47. Taipale P, Orden MR, Berg M, Manninen H, Alafuzoff I. Prenatal diagnosis of placenta accreta and percreta with ultrasonography, color Doppler, and magnetic resonance imaging. *Obstet Gynecol* 2004;104:537-40.
48. Oyelese Y, Smulian JC. Placenta previa, placenta accreta, and vasa previa. *Obstet Gynecol* 2006;107:927-41.
49. Thia EW, Tan LK, Devendra K, Yong TT, Tan HK, Ho TH. Lessons learnt from two women with morbidly adherent placentas and a review of literature. *Ann Acad Med Singapore* 2007;36:298-303.
50. Wong HS, Hutton J, Zuccollo J, Tait J, Pringle KC. The maternal outcome in placenta accreta: The significance of antenatal diagnosis and nonseparation of placenta at delivery. *N Z Med J* 2008;121:30-38.
51. Palacios-Jaraquemada JM. Diagnosis and management of placenta accreta. *Best Pract Res Clin Obstet Gynaecol* 2008;22:1133-48.
52. Dwyer BK, Belogolovkin V, Tran L, et al. Prenatal diagnosis of placenta accreta: Sonography or magnetic resonance imaging? *J Ultrasound Med* 2008;27:1275-81.
53. Wong HS, Cheung YK, Zuccollo J, Tait J, Pringle KC. Evaluation of sonographic diagnostic criteria for placenta accreta. *J Clin Ultrasound* 2008;36:551-59.
54. Baughman WC, Corteville JE, Shah RR. Placenta accreta: Spectrum of US and MR imaging findings. *Radiographics* 2008;28:1905-16.
55. Teo TH, Law YM, Tay KH, Tan BS, Cheah FK. Use of magnetic resonance imaging in evaluation of placental invasion. *Clin Radiol* 2009;64:511-16.
56. Ananth CV, Oyelese Y, Yeo L, Pradhan A, Vintzileos AM. Placental abruption in the United States, 1979 through 2001: temporal trends and potential determinants. *Am J Obstet Gynecol* 2005;192:191-98.
57. Ananth CV, Berkowitz GS, Savitz DA, Lapinski RH. Placental abruption and adverse perinatal outcomes. *JAMA* 1999;282:1646-51.
58. Misra DP, Ananth CV. Risk factor profiles of placental abruption in first and second pregnancies: Heterogeneous etiologies. *J Clin Epidemiol* 1999;52:453-61.
59. Ananth CV, Smulian JC, Vintzileos AM. Incidence of placental abruption in relation to cigarette smoking and hypertensive disorders during pregnancy: A meta-analysis of observational studies. *Obstet Gynecol* 1999;93:622-28.
60. Oyelese Y, Ananth CV. Placental abruption. *Obstet Gynecol* 2006;108:1005-16.
61. Spirt BA, Kagan EH, Rozanski RM. Sonographic anatomy of the normal placenta. *J Clin Ultrasound* 1979;7:204-07.
62. Tikkanen M, Nuutila M, Hiilesmaa V, Paavonen J, Ylikorkala O. Clinical presentation and risk factors of placental abruption. *Acta Obstet Gynecol Scand* 2006;85:700-05.
63. Glantz C, Purnell L. Clinical utility of sonography in the diagnosis and treatment of placental abruption. *J Ultrasound Med* 2002;21:837-40.
64. Nyberg DA, Cyr DR, Mack LA, Wilson DA, Shuman WP. Sonographic spectrum of placental abruption. *AJR Am J Roentgenol* 1987;148:161-64.
65. Sholl JS. Abruptio placentae: Clinical management in nonacute cases. *Am J Obstet Gynecol* 1987;156:40-51.
66. Jaffe MH, Schoen WC, Silver TM, Bowerman RA, Stuck KJ. Sonography of abruptio placentae. *AJR Am J Roentgenol* 1981;137:1049-54.
67. Yeo L AC, Vintzileos A. Placenta Abruption. In: JS, ed. *Gynecology and obstetrics*. Hagerstown (MD): Lippincott, Williams & Wilkins, 2004.
68. Nyberg DA, Mack LA, Benedetti TJ, Cyr DR, Schuman WP. Placental abruption and placental hemorrhage: Correlation of sonographic findings with fetal outcome. *Radiology* 1987;164:357-61.
69. Vaknin Z, Maymon R, Mendlovic S, Barel O, Herman A, Sherman D. Clinical, sonographic, and epidemiologic features of second- and early third-trimester spontaneous antepartum uterine rupture: A cohort study. *Prenat Diagn* 2008;28:478-84.
70. Acton CM, Long PA. The ultrasonic appearance of a ruptured uterus. *Australas Radiol* 1978;22:254-56.
71. Suonio S, Saarikoski S, Kaariainen J, Virtanen R. Intrapartum rupture of uterus diagnosed by ultrasound: A case report. *Int J Gynaecol Obstet* 1984;22:411-13.
72. Bedi DG, Salmon A, Winsett MZ, Fagan CJ, Kumar R. Ruptured uterus: Sonographic diagnosis. *J Clin Ultrasound* 1986;14: 529-33.
73. Gale JT, Mahony BS, Bowie JD. Sonographic features of rupture of the pregnant uterus. *J Ultrasound Med* 1986;5:713-14.
74. Avrech OM, Weinraub Z, Herman A, et al. Ultrasonic antepartum assessment of a classical Cesarean uterine scar and diagnosis of dehiscence. *Ultrasound Obstet Gynecol* 1994;4:151-53.
75. van Alphen M, van Vugt JM, Hummel P, van Geijn HP. Recurrent uterine rupture diagnosed by ultrasound. *Ultrasound Obstet Gynecol* 1995;5:419-21.
76. Bujold E, Jastrow N, Simoneau J, Brunet S, Gauthier RJ. Prediction of complete uterine rupture by sonographic evaluation of the lower uterine segment. *Am J Obstet Gynecol* 2009;201:320 e1-6.
77. Bergeron ME, Jastrow N, Brassard N, Paris G, Bujold E. Sonography of lower uterine segment thickness and prediction of uterine rupture. *Obstet Gynecol* 2009;113:520-22.
78. Cheung VY. Sonographic measurement of the lower uterine segment thickness in women with previous caesarean section. *J Obstet Gynaecol Can* 2005;27:674-81.

79. Jastrow N, Antonelli E, Robyr R, Irion O, Boulvain M. Inter- and intraobserver variability in sonographic measurement of the lower uterine segment after a previous Cesarean section. *Ultrasound Obstet Gynecol* 2006;27:420-24.
80. Sebire NJ, Sepulveda W. Correlation of placental pathology with prenatal ultrasound findings. *J Clin Pathol* 2008;61:1276-84.
81. Wittmann BK, Fulton L, Cooperberg PL, Lyons EA, Miller C, Shaw D. Molar pregnancy: Early diagnosis by ultrasound. *J Clin Ultrasound* 1981;9:153-56.
82. Fleischer AC, James AE (Jr), Krause DA, Millis JB. Sonographic patterns in trophoblastic diseases. *Radiology* 1978;126:215-20.
83. Hou JL, Wan XR, Xiang Y, Qi QW, Yang XY. Changes of clinical features in hydatidiform mole: Analysis of 113 cases. *J Reprod Med* 2008;53:629-33.
84. Gemer O, Segal S, Kopmar A, Sassoon E. The current clinical presentation of complete molar pregnancy. *Arch Gynecol Obstet* 2000;264:33-34.
85. Cox SM, Klein VR. Partial molar pregnancy associated with severe pregnancy-induced hypertension. *J Perinatol* 1993;13:103-06.
86. Berkowitz RS, Goldstein DP, Bernstein MR. Evolving concepts of molar pregnancy. *J Reprod Med* 1991;36:40-44.
87. Niemann I, Petersen LK, Hansen ES, Sunde L. Differences in current clinical features of diploid and triploid hydatidiform mole. *BJOG* 2007;114:1273-77.
88. Brittain PC, Bayliss P. Partial hydatidiform molar pregnancy presenting with severe pre-eclampsia prior to twenty weeks gestation: A case report and review of the literature. *Mil Med* 1995;160:42-44.
89. Woo JS, Hsu C, Fung LL, Ma HK. Partial hydatidiform mole: Ultrasonographic features. *Aust NZJ Obstet Gynaecol* 1983;23:103-07.
90. Naumoff P, Szulman AE, Weinstein B, Mazer J, Surti U. Ultrasonography of partial hydatidiform mole. *Radiology* 1981;140:467-70.
91. Benson CB, Genest DR, Bernstein MR, Soto-Wright V, Goldstein DP, Berkowitz RS. Sonographic appearance of first trimester complete hydatidiform moles. *Ultrasound Obstet Gynecol* 2000;16:188-91.
92. Lazarus E, Hulka C, Siewert B, Levine D. Sonographic appearance of early complete molar pregnancies. *J Ultrasound Med* 1999;18:589-94; quiz 595-96.
93. Prando A, Bernardino ME. Ultrasonography in trophoblastic disease. *South Med J* 1979;72:297-99.
94. Santos-Ramos R, Forney JP, Schwarz BE. Sonographic findings and clinical correlations in molar pregnancy. *Obstet Gynecol* 1980;56:186-92.
95. Zaki ZM, Bahar AM. Ultrasound appearance of a developing mole. *Int J Gynaecol Obstet* 1996;55:67-70.
96. Alhamdan D, Bignardi T, Condous G. Recognising gestational trophoblastic disease. *Best Pract Res Clin Obstet Gynaecol* 2009;23:565-73.
97. Jauniaux E. Partial moles: From postnatal to prenatal diagnosis. *Placenta* 1999;20:379-88.
98. Taylor KJ, Schwartz PE, Kohorn EI. Gestational trophoblastic neoplasia: Diagnosis with Doppler US. *Radiology* 1987;165:445-48.
99. Dobkin GR, Berkowitz RS, Goldstein DP, Bernstein MR, Doubilet PM. Duplex ultrasonography for persistent gestational trophoblastic tumor. *J Reprod Med* 1991;36:14-16.
100. Griffin DW, Strand EA. Arteriovenous malformation of the uterus after a midtrimester loss: A case report. *J Reprod Med* 2009;54:333-36.
101. Rufener SL, Adusumilli S, Weadock WJ, Caoili E. Sonography of uterine abnormalities in postpartum and postabortion patients: A potential pitfall of interpretation. *J Ultrasound Med* 2008;27:343-48.
102. Nasu K, Yamaguchi M, Yoshimatsu J, Miyakawa I. Pregnancy complicated by asymptomatic uterine arteriovenous malformation: A case report. *J Reprod Med* 2007;52:335-37.
103. Delotte J, Chevallier P, Benoit B, Castillon JM, Bongain A. Pregnancy after embolization therapy for uterine arteriovenous malformation. *Fertil Steril* 2006;85:228.
104. Kwon JH, Kim GS. Obstetric iatrogenic arterial injuries of the uterus: Diagnosis with US and treatment with transcatheter arterial embolization. *Radiographics* 2002;22:35-46.
105. Hoffman MK, Meilstrup JW, Shackelford DP, Kaminski PF. Arteriovenous malformations of the uterus: An uncommon cause of vaginal bleeding. *Obstet Gynecol Surv* 1997;52:736-40.